OBJECTIVE: The aim of this study was to evaluate the effects of using ACE 
inhibitors on insulin resistance, glucose metabolism, body fat composition, and 
lipid profile in children over 10 years of age with obesity-associated metabolic 
syndrome (MS).
METHODS: A total of 53 children with MS, who had been followed for at least one 
year were included in the study. The sample was divided into two groups: Group 
1-30 obese children (13 female, 17 male) who were not using an ACE inhibitor and 
Group 2-23 obese children (13 female, 10 male) who were using an ACE inhibitor. 
Anthropometric and laboratory data obtained at baseline and at the 3rd, 6th, and 
12th months of follow-up were compared in the two groups.
RESULTS: Comparison of the data in the two groups at 3rd, 6th, and 12th months 
revealed no statistically significant differences in terms of weight standard 
deviation score (SDS), body mass index SDS, weight for height percentile, body 
fat percentage, and very low-density lipoprotein (VLDL)values. However, there 
were statistically significant differences in mean glucose and insulin levels, 
homeostasis model assessment for insulin resistance, LDL and high-density 
lipoprotein values, and highly significant differences in mean triglyceride 
values.
CONCLUSIONS: The positive effects of ACE inhibitor drugs, particularly on 
hypertriglyceridemia and insulin resistance, might bring them forth as 
first-line drugs in the treatment of obese and hypertensive children. 
Randomized, controlled, double-blind, and long-term studies are needed for a 
definitive conclusion.